Our screen of 774 FDA-approved drugs identified nine compounds that showed an increased toxicity in the genetically edited U2OS osteosarcoma cells, which lack NMNAT1, compared to their wild type counterparts (Figure 1). Here, NMNAT1 is linked to osteosarcoma.